



CODEN [USA]: IAJ PBB

ISSN: 2349-7750

**INDO AMERICAN JOURNAL OF
PHARMACEUTICAL SCIENCES**<http://doi.org/10.5281/zenodo.3369911>Available online at: <http://www.iajps.com>

Research Article

**HEMATOLOGICAL EVALUATION OF PATIENTS WITH
HELICOBACTER PYLORI INFECTION**

¹Dr. Nand Lal Seerani, ²Dr. Jetesh Kumar, ¹Dr. Tarachand Devrajani,
²Dr. Shumaila Khalil, ²Dr. Samar Raza and ¹Dr. Syed Zulfiqar Ali Shah
¹Liaquat University of Medical and Health Sciences (LUMHS) Jamshoro, ²Liaquat University
Hospital Hyderabad / Jamshoro, ³Zulekha Hospital Dubai United Arab Emirates

Article Received: June 2019 **Accepted:** July 2019 **Published:** August 2019**Abstract:**

Objective: To evaluate the hematological features of patients with helicobacter pylori infection.

Patients And Methods: A total of fifty patients of Helicobacter pylori infection were explored and included in the study. The cross-sectional survey includes patients of ≥ 18 year of age diagnosed as H. pylori infection either gender while the exclusion criteria were patients with pregnant and lactating mothers, already on chemotherapy, iron and vitamin B12 supplements, known cases of hematological malignancy and history of blood transfusion and the participants who refused to give consent for the study. The hematological parameters will be explored through clinical history examination, physical examination and specific investigations as required whereas the frequency / percentages (%) and means \pm SD computed for study variables.

Results: During six month study period total fifty patients with H. pylori were explored and study. The mean \pm SD for age (yrs) of population was 42.74 ± 6.75 . Regarding gender distribution male 35 (70%) and female 15 (30%). Regarding the hematological manifestation iron deficiency 25 (50%), vitamin B12 (cobalamina) deficiency 10 (20%), Gastric MALT lymphoma 04 (8.0%) and Immune thrombocytopenia 11 (22%).

Conclusion: The acknowledgment of hematologic infections related with H. pylori contamination and their consideration as signs for study.

Keyword's: Helicobacter pylori, hematology and iron deficiency anemia.

Corresponding author:**Dr. Syed Zulfiqar Ali Shah,**

Liaquat University of Medical and Health Sciences (LUMHS) Jamshoro.

Email: zulfikar229@hotmail.com

QR code



Please cite this article in press Syed Zulfiqar Ali Shah et al., *Hematological Evaluation Of Patients With Helicobacter Pylori Infection.*, Indo Am. J. P. Sci, 2019; 06[08].

INTRODUCTION:

Helicobacter pylori (*H. pylori*) is a gram-negative, microaerophilic, winding molded and lashed bacterium contaminating about a large portion of the total populace whose principle store is the human stomach. The predominance of contamination changes by geographic territory, age, ethnicity and financial status; truth be told, the pervasiveness is higher in developing nations and in those with poor financial conditions [1, 2]. *H. pylori* has microbiological qualities that enable it to make due in incredibly unfavorable conditions, for example, the gastric acidic condition. Transmission of the disease happens essentially through the oral-fecal route [3], specifically through polluted water and sustenance. Oral-oral transmission is likewise conceivable, as appeared by the confinement of the bacterium in salivation and dental plaque. In the 30 years that have passed since its disclosure, more than 50 extragastric indications of *H. pylori* disease have been accounted for, including a scope of medicinal specializations including dermatology, gynecology and obstetrics, cardiology, endocrinology, pulmonology, ophthalmology, otorhinolaryngology, nervous system science, pediatric medicine, odontology and hematology [4-6]. Hematological signs are the subject of this audit. Hematological pattern that are perceived as extragastric appearances of *H. pylori*

disease and considered as hematological dysfunction that ought not be just tended to but rather needs to oversee on need premise to counteract the patient procure perilous inconveniences.

PATIENTS AND METHODS:

A total of fifty patients of *Helicobacter pylori* infection were explored and included in the study. The cross-sectional survey includes patients of ≥ 18 year of age diagnosed as *H. pylori* infection either gender while the exclusion criteria were patients with pregnant and lactating mothers, already on chemotherapy, iron and vitamin B12 supplements, known cases of hematological malignancy and history of blood transfusion and the participants who refused to give consent for the study. The hematological parameters will be explored through clinical history examination, physical examination and specific investigations as required. The data was collected on pre-designed proforma and analyzed in SPSS to manipulate the frequencies and percentages.

RESULTS:

During six month study period total fifty patients with *H. pylori* were explored and study. The mean \pm SD for age (yrs) of population was 42.74 ± 6.75 . The demographical and clinical profile of study population is presented in Table 1.

TABLE 1: The Demographical And Clinical Profile Of Study Population

Parameter	Frequency (N=50)	Percentage (%)
AGE (yrs)		
20-29	10	20
30-39	12	24
40-49	14	28
50-59	08	16
60+	06	12
GENDER		
Male	35	70
Female	15	30
RESIDENCE		
Urban	29	58
Rural	21	42
CO-MORBIDITIES		
Obesity	22	44
Dyslipidemia	12	24
Diabetes Mellitus	20	40
Hypertension	18	36
HEMATOLOGICAL MANIFESTATION		
Iron deficiency	25	50
Vitamin B12 (cobalamina) deficiency	10	20
Gastric MALT lymphom	04	8.0
Immune thrombocytopenia	11	22

DISCUSSION:

The connection between *H. pylori* and iron lacks, paying little respect to whether the last is joined by pallor, was first portrayed by Blecker et al[7] in Belgium. All previous distribution have loaned logical help to the diverse worldwide rules that show that *H. pylori* ought to be looked for and destroyed in iron lack cases. Pernicious anemia as a phase of interminable nutrient B12 deficient was the first extragastric infection to be related with *H. pylori* disease, as hypothesized in established researchers by O'Connor et al [8]. Also, it was realized that there was a relationship of *H. pylori* with stomach disease, and it was at that point broadly perceived by mainstream researchers that that pernicious anemia was firmly identified with the advancement of stomach cancer[9]. This affiliation was as of late checked by Vanella et al[10]. Garcia Perez et al [11] depicted the relationship of *H. pylori* with immune thrombocytopenic purpura without precedent for 1993 in Spain, detailing a patient with immune thrombocytopenic purpura in whom the platelet tally was standardized after annihilation of *H. pylori*. Since the main arrangement substantiated the relationship of *H. pylori* contamination with immune thrombocytopenic purpura [12], it is conceivable to discover 40 extra case arrangements in the therapeutic writing in 2014 that reliably demonstrate the relationship of *H. pylori* annihilation with the recuperation of platelet tallies. Extranodal minimal zone lymphoma, better known by the abbreviation MALT lymphoma, is characterized as a poor quality harmful lymphoma of the stomach starting from B cells and is related with constant disease by *H. pylori*[13].

CONCLUSION:

The acknowledgment of hematologic infections related with *H. pylori* contamination and their consideration as signs for study and destruction speaks to a profound change in the treatment worldview of these illnesses and an incredible achievement for humanity

REFERENCES:

1. Correa P. Gastric cancer: overview. *Gastroenterol Clin North Am* 2013; 42: 211-217
2. Stolte M, Bayerdörffer E, Morgner A, Alpen B, Wündisch T, Thiede C, Neubauer A. Helicobacter and gastric MALT lymphoma. *Gut* 2002; 50 Suppl 3: III19-III24
3. Gasbarrini A, Franceschi F, Armuzzi A, Ojetti V, Candelli M, Torre ES, De Lorenzo A, Anti M, Pretolani S, Gasbarrini G. Extradigestive manifestations of Helicobacter pylori gastric infection. *Gut* 1999; 45 Suppl 1: I9-I12
4. Realdi G, Dore MP, Fastame L. Extradigestive manifestations of Helicobacter pylori infection: fact and fiction. *Dig Dis Sci* 1999; 44: 229-236
5. Carloni E, Cremonini F, Di Caro S, Padalino C, Gerardino L, Santoliquido A, Colasanti S, Pola P, Gasbarrini A. Helicobacter pylori-related extradigestive diseases and effects of eradication therapy. *Dig Liver Dis* 2000; 32 Suppl 3: S214-S216
6. De Koster E, De Bruyne I, Langlet P, Deltenre M. Evidencebased medicine and extradigestive manifestations of Helicobacter pylori. *Acta Gastroenterol Belg* 2000; 63: 388-392
7. Blecker U, Renders F, Lanciers S, Vandenplas Y. Syncope leading to the diagnosis of a Helicobacter pylori positive chronic active haemorrhagic gastritis. *Eur J Pediatr* 1991; 150: 560-561
8. O'Connor HJ, Axon AT, Dixon MF. Campylobacter-like organisms unusual in type A (pernicious anaemia) gastritis. *Lancet* 1984; 2: 1091
9. Zamcheck N, Grable E, Ley A, Norman L. Occurrence of gastric cancer among patients with pernicious anemia at the Boston City Hospital. *N Engl J Med* 1955; 252: 1103-1110
10. Vannella L, Lahner E, Osborn J, Annibale B. Systematic review: gastric cancer incidence in pernicious anaemia. *Aliment Pharmacol Ther* 2013; 37: 375-382
11. Garcia Perez A, Valverde de La Osa J, Giménez Samper M, Alonso García I. Resolution of an autoimmune thrombocytopenic purpura after eradicating treatment of Helicobacter pylori. *Sangre (Barc)* 1999; 44: 387-388
12. Gasbarrini A, Franceschi F, Tartaglione R, Landolfi R, Pola P, Gasbarrini G. Regression of autoimmune thrombocytopenia after eradication of Helicobacter pylori. *Lancet* 1998; 352: 878
13. Claviez A, Meyer U, Dominick C, Beck JF, Rister M, Tiemann M. MALT lymphoma in children: a report from the NHL-BFM Study Group. *Pediatr Blood Cancer* 2006; 47: 210-214